Shanghai Jingong Enterprise Development

Shanghai Jingong Enterprise Development is a key industrial platform and infrastructure development company based in the Bay Area High-Tech Zone of Jinshan District, Shanghai. Established in 2010, the company functions as a specialized partner for the biopharmaceutical industry, focusing on the development and renovation of industrial parks and manufacturing facilities. In early 2026, the company entered into a major strategic partnership with CARsgen Therapeutics to establish an advanced commercial manufacturing base for CAR T-cell therapies. This collaboration involves a total investment of approximately RMB 370 million to create high-standard production environments for innovative products such as zevorcabtagene autoleucel and satricabtagene autoleucel. As a wholly-owned subsidiary of the state-owned Shanghai Xinjinshan Industrial Investment Development, the company plays a pivotal role in strengthening Shanghai's cell therapy ecosystem and supporting the global commercialization of advanced biotherapeutics.